Previous 10 | Next 10 |
Prothena (NASDAQ:PRTA): Q2 GAAP EPS of $0.58 misses by $0.30. Revenue of $60.07M (+31515.8% Y/Y) misses by $13.47M. Press Release For further details see: Prothena EPS misses by $0.30, misses on revenue
Net cash provided by operating and investing activities was $36.6 million in the second quarter and $2.9 million for the first six months of 2021; quarter-end cash and restricted cash position of $402.5 million (includes $60 million payment from Roche) provides additional funding to con...
DUBLIN, Ireland, July 29, 2021 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical company with a robust pipeline of novel investigational therapeutics built on protein dysregulation expertise, announced today that it will report its second quarter and first si...
travellinglight/iStock via Getty Images Prothena (PRTA) presents new data at the AAIC 2021 from two of its Alzheimer’s disease ((AD)) programs. The presentations highlight new data for PRX012, the next-generation anti-amyloid beta (Aβ) antibody being developed for subcutane...
Late-breaking PRX012 poster highlights significant ex vivo clearance of both pyroglutamate-modified and -unmodified Aβ plaque from AD brain at concentrations expected to be reached in CNS with subcutaneous administration Poster presentation demonstrates dual Aβ-tau v...
Novo Nordisk (NYSE: NVO) recently announced that it's buying Prothena 's (NASDAQ: PRTA) transthetyrin amyloidosis (ATTR) cardiomyopathy program for up to $1.2 billion. In this Motley Fool Live video recorded on July 14, 2021 , Motley Fool contributors Keith Spei...
Prothena is a $2.25bn market cap biotech with a unique, epitope targeting approach to drug development. The company has resurrected its AL Amyloidosis drug Birtamimab and has a pivotal trial ongoing in high risk patients. Prothena has 3 major pharmaceutical partners - Roche in Par...
Biotech stocks had a muted first half with the S&P Biotech Index down year-to-date, and more than 20% lower from its mid-February peak. The decline in biotech stocks coincided with a spike in interest rates and stabilizing interest rates can provide a boost to valuations. M&am...
DUBLIN, Ireland, July 20, 2021 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical company with a robust pipeline of novel investigational therapeutics built on protein dysregulation expertise, today announced that it will present preclinical data on two of its...
weisschr/iStock via Getty Images Shares of Prothena ([[PRTA]] -9.6%) are struggling in afternoon trading even though the company earlier today signed a deal with Novo Nordisk ([[NVO]] +0.0%) earlier today potentially worth as much as $1.2B. That agreement calls for Novo to acquire Prothe...
News, Short Squeeze, Breakout and More Instantly...
Prothena Corporation plc Company Name:
PRTA Stock Symbol:
NASDAQ Market:
Prothena Corporation plc Website:
2024-07-03 23:18:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-06-02 10:04:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Prothena to receive $80 million from Bristol Myers Squibb for exclusive global license to PRX019, a potential treatment of neurodegenerative diseases with an undisclosed target Prothena will initiate a Phase 1 clinical trial for PRX019 in 2024 Prothena Corporation plc (NASDAQ:PRTA),...